Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
57,148,979
-
Total 13F shares
-
33,460,789
-
Share change
-
+1,417,939
-
Total reported value
-
$206,451,772
-
Put/Call ratio
-
57%
-
Price per share
-
$6.17
-
Number of holders
-
94
-
Value change
-
+$9,368,489
-
Number of buys
-
46
-
Number of sells
-
39
Institutional Holders of Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN) as of Q4 2024
As of 31 Dec 2024,
Design Therapeutics, Inc. - Common Stock, par value $0.0001 per share (DSGN) was held by
94 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
33,460,789 shares.
The largest 10 holders included
SR One Capital Management, LP, Logos Global Management LP, BlackRock, Inc., Frazier Life Sciences Management, L.P., Point72 Asset Management, L.P., BAKER BROS. ADVISORS LP, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, Almitas Capital LLC, and CITADEL ADVISORS LLC.
This page lists
94
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.